ROS1 and non-small cell lung carcinoma: Particularly with regards to ALK and ROS1, which are found at rates of 1.5% and 0.3%, respectively, in data from Quebec and in 1–7% of patients with NSCLC in other studies [48,49], immunotherapy is not thought to be effective.